|

ONC-PluReceptor NK cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1

Indications

  • Refractory B-Cell Non-Hodgkin Lymphoma1
  • Recurrent B-Cell Non-Hodgkin Lymphoma1
  • Cancer1

Houston, Texas1 trial

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.